Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gastric Cancer

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 58 articles: HTML format

Single Articles

June 2021
1. LEE IS, Ahn J, Kim K, Okugawa Y, et al
   A blood-based transcriptomic signature for noninvasive diagnosis of gastric cancer.
   Br J Cancer. 2021 Jun 23. pii: 10.1038/s41416-021-01461.
   PubMed     Abstract available
   
   
   April 2021
2. TANAKA H, Kanda M, Miwa T, Umeda S, et al
   G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer.
   Br J Cancer. 2021 Apr 14. pii: 10.1038/s41416-021-01366.
   PubMed     Abstract available
   
   
   March 2021
3. TAKASHIMA T, Taniyama D, Sakamoto N, Yasumoto M, et al
   Schlafen 11 predicts response to platinum-based chemotherapy in gastric cancers.
   Br J Cancer. 2021 Mar 30. pii: 10.1038/s41416-021-01364.
   PubMed     Abstract available
   
   
   February 2021
4. MIWA T, Kanda M, Shimizu D, Umeda S, et al
   Hepatic metastasis of gastric cancer is associated with enhanced expression of ethanolamine kinase 2 via the p53-Bcl-2 intrinsic apoptosis pathway.
   Br J Cancer. 2021 Feb 3. pii: 10.1038/s41416-021-01271.
   PubMed     Abstract available
   
   
   October 2020
5. SAITO R, Shoda K, Maruyama S, Yamamoto A, et al
   Platelets enhance malignant behaviours of gastric cancer cells via direct contacts.
   Br J Cancer. 2020 Oct 28. pii: 10.1038/s41416-020-01134.
   PubMed     Abstract available
   
   
   
6. YAMASHITA K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, et al
   Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
   Br J Cancer. 2020 Oct 26. pii: 10.1038/s41416-020-01138.
   PubMed     Abstract available
   
   
   
7. OPENSHAW MR, Mohamed AA, Ottolini B, Fernandez-Garcia D, et al
   Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma.
   Br J Cancer. 2020;123:1271-1279.
   PubMed     Abstract available
   
   
   September 2020
8. ZHAO J, Fu X, Chen H, Min L, et al
   G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer.
   Br J Cancer. 2020 Sep 29. pii: 10.1038/s41416-020-01067.
   PubMed     Abstract available
   
   
   
9. JUNTTILA A, Helminen O, Vayrynen JP, Ahtiainen M, et al
   Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer.
   Br J Cancer. 2020 Sep 18. pii: 10.1038/s41416-020-01053.
   PubMed     Abstract available
   
   
   
10. SHIMURA T, Dayde D, Wang H, Okuda Y, et al
    Novel urinary protein biomarker panel for early diagnosis of gastric cancer.
    Br J Cancer. 2020 Sep 16. pii: 10.1038/s41416-020-01063.
    PubMed     Abstract available
    
    
    July 2020
11. HAGI T, Kurokawa Y, Kawabata R, Omori T, et al
    Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.
    Br J Cancer. 2020 Jul 3. pii: 10.1038/s41416-020-0975.
    PubMed     Abstract available
    
    
    
12. LIN JX, Yoon C, Li P, Ryeom SW, et al
    CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer.
    Br J Cancer. 2020 Jul 1. pii: 10.1038/s41416-020-0963.
    PubMed     Abstract available
    
    
    June 2020
13. KIM JH, Han KD, Lee JK, Kim HS, et al
    Correction: Association between the National Cancer Screening Programme (NSCP) for gastric cancer and oesophageal cancer mortality.
    Br J Cancer. 2020 Jun 17. pii: 10.1038/s41416-020-0946.
    PubMed     Abstract available
    
    
    May 2020
14. LIN JP, Lin JX, Ma YB, Xie JW, et al
    Prognostic significance of pre- and post-operative tumour markers for patients with gastric cancer.
    Br J Cancer. 2020 May 26. pii: 10.1038/s41416-020-0901.
    PubMed     Abstract available
    
    
    
15. NATSUME M, Shimura T, Iwasaki H, Okuda Y, et al
    Omental adipocytes promote peritoneal metastasis of gastric cancer through the CXCL2-VEGFA axis.
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0898.
    PubMed     Abstract available
    
    
    
16. KIM JH, Han KD, Lee JK, Kim HS, et al
    Association between the National Cancer Screening Programme (NSCP) for gastric cancer and oesophageal cancer mortality.
    Br J Cancer. 2020 May 13. pii: 10.1038/s41416-020-0883.
    PubMed     Abstract available
    
    
    
17. LIU P, McMenamin UC, Johnston BT, Murchie P, et al
    Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.
    Br J Cancer. 2020 May 5. pii: 10.1038/s41416-020-0860.
    PubMed     Abstract available
    
    
    April 2020
18. GAO Y, Li J, Xi H, Cui J, et al
    Stearoyl-CoA-desaturase-1 regulates gastric cancer stem-like properties and promotes tumour metastasis via Hippo/YAP pathway.
    Br J Cancer. 2020 Apr 30. pii: 10.1038/s41416-020-0827.
    PubMed     Abstract available
    
    
    
19. LIU HT, Ma RR, Lv BB, Zhang H, et al
    LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K/AKT signalling pathway by sponging miR-30b-3p in gastric cancer.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0836.
    PubMed     Abstract available
    
    
    March 2020
20. LI R, Liu H, Cao Y, Wang J, et al
    Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103(+)CD8(+) T cells conferring favourable prognosis.
    Br J Cancer. 2020 Mar 24. pii: 10.1038/s41416-020-0813.
    PubMed     Abstract available
    
    
    
21. WU C, Ding H, Wang S, Li Y, et al
    DAXX inhibits cancer stemness and epithelial-mesenchymal transition in gastric cancer.
    Br J Cancer. 2020 Mar 23. pii: 10.1038/s41416-020-0800.
    PubMed     Abstract available
    
    
    
22. OHMURA H, Yamaguchi K, Hanamura F, Ito M, et al
    OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody.
    Br J Cancer. 2020 Mar 23. pii: 10.1038/s41416-020-0810.
    PubMed     Abstract available
    
    
    
23. KWAK Y, Koh J, Park Y, Hong YJ, et al
    Differential prognostic impact of CD8(+) T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0793.
    PubMed     Abstract available
    
    
    November 2019
24. ICHIKAWA T, Okugawa Y, Toiyama Y, Tanaka K, et al
    Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer.
    Br J Cancer. 2019 Nov 22. pii: 10.1038/s41416-019-0646.
    PubMed     Abstract available
    
    
    October 2019
25. MASHIMA T, Iwasaki R, Kawata N, Kawakami R, et al
    In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells.
    Br J Cancer. 2019 Oct 14. pii: 10.1038/s41416-019-0600.
    PubMed     Abstract available
    
    
    August 2019
26. LIU Z, Cheng X, Zhang L, Zhou J, et al
    A panel of DNA methylated markers predicts metastasis of pN0M0 gastric carcinoma: a prospective cohort study.
    Br J Cancer. 2019 Aug 21. pii: 10.1038/s41416-019-0552.
    PubMed     Abstract available
    
    
    July 2019
27. YAMASHITA K, Iwatsuki M, Harada K, Koga Y, et al
    Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
    Br J Cancer. 2019 Jul 9. pii: 10.1038/s41416-019-0515.
    PubMed     Abstract available
    
    
    
28. COATI I, Lotz G, Fanelli GN, Brignola S, et al
    Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases.
    Br J Cancer. 2019;121:257-263.
    PubMed     Abstract available
    
    
    June 2019
29. ZHENG J, Rutegard M, Santoni G, Wallner B, et al
    Prediabetes and diabetes in relation to risk of gastric adenocarcinoma.
    Br J Cancer. 2019;120:1147-1152.
    PubMed     Abstract available
    
    
    March 2019
30. KIM JH, Eom HJ, Lim G, Park S, et al
    Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 alpha inhibitor BI6015.
    Br J Cancer. 2019;120:488-498.
    PubMed     Abstract available
    
    
    
31. FORNARO L, Vivaldi C, Parnofiello A, Ugolini C, et al
    Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer.
    Br J Cancer. 2019;120:522-526.
    PubMed     Abstract available
    
    
    July 2018
32. KNODLER M, Korfer J, Kunzmann V, Trojan J, et al
    Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
    Br J Cancer. 2018 Jul 10. pii: 10.1038/s41416-018-0150.
    PubMed     Abstract available
    
    
    March 2018
33. XIN L, Yang WF, Zhang HT, Li YF, et al
    The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin.
    Br J Cancer. 2018 Mar 26. pii: 10.1038/s41416-018-0043.
    PubMed     Abstract available
    
    
    
34. SHIMADA S, Akiyama Y, Mogushi K, Ishigami-Yuasa M, et al
    Identification of selective inhibitors for diffuse-type gastric cancer cells by screening of annotated compounds in preclinical models.
    Br J Cancer. 2018 Mar 12. pii: 10.1038/s41416-018-0008.
    PubMed     Abstract available
    
    
    February 2018
35. MIKI Y, Yashiro M, Okuno T, Kitayama K, et al
    CD9-positive exosomes from cancer-associated fibroblasts stimulate the migration ability of scirrhous-type gastric cancer cells.
    Br J Cancer. 2018 Feb 13. pii: bjc2017487. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    
36. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Abstract available
    
    
    
37. NIEMINEN MT, Listyarifah D, Hagstrom J, Haglund C, et al
    Treponema denticola chymotrypsin-like proteinase may contribute to orodigestive carcinogenesis through immunomodulation.
    Br J Cancer. 2018;118:428-434.
    PubMed     Abstract available
    
    
    January 2018
38. AJANI JA, Estrella JS, Chen Q, Correa AM, et al
    Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors.
    Br J Cancer. 2018;118:52-61.
    PubMed     Abstract available
    
    
    December 2017
39. WANG X, Zhao DB, Yang L, Chi Y, et al
    S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017424. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    November 2017
40. FANG C, Wang W, Feng X, Sun J, et al
    Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Br J Cancer. 2017;117:1544-1550.
    PubMed     Abstract available
    
    
    October 2017
41. SEO AN, Kang BW, Kwon OK, Park KB, et al
    Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Br J Cancer. 2017 Oct 26. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    September 2017
42. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Abstract available
    
    
    
43. ALMEIDA GS, Panek R, Hallsworth A, Webber H, et al
    Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform.
    Br J Cancer. 2017;117:791-800.
    PubMed     Abstract available
    
    
    August 2017
44. JIMENEZ FONSECA P, Carmona-Bayonas A, Hernandez R, Custodio A, et al
    Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    June 2017
45. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Abstract available
    
    
    
46. KUROKAWA Y, Yang HK, Cho H, Ryu MH, et al
    Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach.
    Br J Cancer. 2017;117:25-32.
    PubMed     Abstract available
    
    
    
47. SIERZEGA M, Kaczor M, Kolodziejczyk P, Kulig J, et al
    Evaluation of serum microRNA biomarkers for gastric cancer based on blood and tissue pools profiling: the importance of miR-21 and miR-331.
    Br J Cancer. 2017 Jun 22. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    
48. ZHANG P, Tang WM, Zhang H, Li YQ, et al
    MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    
49. CUSTODIO A, Carmona-Bayonas A, Jimenez-Fonseca P, Sanchez ML, et al
    Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.
    Br J Cancer. 2017;116:1526-1535.
    PubMed     Abstract available
    
    
    April 2017
50. WENNERSTROM ECM, Simonsen J, Camargo MC, Rabkin CS, et al
    Acid-suppressing therapies and subsite-specific risk of stomach cancer.
    Br J Cancer. 2017;116:1234-1238.
    PubMed     Abstract available
    
    
    March 2017
51. PETRICK JL, Kelly SP, Liao LM, Freedman ND, et al
    Body weight trajectories and risk of oesophageal and gastric cardia adenocarcinomas: a pooled analysis of NIH-AARP and PLCO Studies.
    Br J Cancer. 2017;116:951-959.
    PubMed     Abstract available
    
    
    
52. BAI T, Yokobori T, Altan B, Ide M, et al
    High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.
    Br J Cancer. 2017 Mar 23. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    
53. SONG Y, Wang Y, Tong C, Xi H, et al
    A unified model of the hierarchical and stochastic theories of gastric cancer.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    February 2017
54. WANG Z, Koh WP, Jin A, Wang R, et al
    Composite protective lifestyle factors and risk of developing gastric adenocarcinoma: the Singapore Chinese Health Study.
    Br J Cancer. 2017;116:679-687.
    PubMed     Abstract available
    
    
    
55. LIANG X, Shi H, Yang L, Qiu C, et al
    Inhibition of polypyrimidine tract-binding protein 3 induces apoptosis and cell cycle arrest, and enhances the cytotoxicity of 5- fluorouracil in gastric cancer cells.
    Br J Cancer. 2017 Feb 21. doi: 10.1038/bjc.2017.
    PubMed     Abstract available
    
    
    January 2017
56. LI P, Chen H, Chen S, Mo X, et al
    Circular RNA 0000096 affects cell growth and migration in gastric cancer.
    Br J Cancer. 2017 Jan 12. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    December 2016
57. KODAMA H, Murata S, Ishida M, Yamamoto H, et al
    Prognostic impact of CD44-positive cancer stem-like cells at the invasive front of gastric cancer.
    Br J Cancer. 2016 Dec 8. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    
    November 2016
58. OHASHI T, Komatsu S, Ichikawa D, Miyamae M, et al
    Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: